Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.

Sci Rep · 2017 · PMC5430907 · PMID 28442763

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP = 0.09so close (0.05 < p ≤ 0.1)

Although HR−HER2+ MBC showed a trend towards a higher incidence of visceral metastases (66.5% vs. 59.6%; P = 0.09), the difference did not reach statistical significance.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

59.6%; P = 0.09), the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.